Clinical Trials

36 studies in Oncology in Minnesota

  1. A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
    1. Minnesota
  2. A Phase 1b Study of LY2835219 in Combination With Endocrine Therapies for Patients With Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
    1. Minnesota
  3. Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
    1. Minnesota
  4. A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
    1. Minnesota
  5. Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy
    1. Florida,
    2. Minnesota
  6. A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
    1. Minnesota
  7. An Open-Label, Multi-Center, Randomized Phase 1b/2 Study Of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
    1. Minnesota
  8. A Phase II Study of Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
    1. Minnesota
  9. A Pilot Randomized, Placebo-Controlled Study to Test Auranofin (Ridaura®) to Control the Paclitaxel-Induced Pain Syndrome (PIAPS)
    1. Minnesota
  10. MC1351: PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
    1. Arizona,
    2. Florida,
    3. Minnesota
  1. 1
  2. 2
  3. 3
  4. 4
  5. Next